Transforming Treatment of Advanced/Metastatic Cutaneous Squamous Cell Carcinoma: Current Treatment

CONTINUING MEDICAL EDUCATION

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation for Physicians

AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ for each component of the 3-part series. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com

Fee Information

There is no fee for this educational activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. 

Disclosure of Conflicts of Interest 

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. 

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Omid Hamid, MD, reported a financial interest/relationship or affiliation in the form of Consultant, Amgen, Inc, Novartis Pharmaceuticals Corp, Roche, Bristol-Myers Squibb Co, Merck & Co, Inc; Contracted research, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Co, Celldex, Inc, Genentech, Inc, Immunocore, Incyte Corp, Merck & Co, Inc, Merck Serano, MedImmune, Novartis Pharmaceuticals Corp, Pfizer, Inc, Rinat, Roche; Speakers' bureau, Bristol-Myers Squibb Co, Genentech, Inc, Novartis Pharmaceuticals Corp, Amgen, Inc.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Stephanie Sutphin, PharmD; and Emma Nichols, PhD state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Chrysalyne D. Schmults, MD, MSCE, reported a financial interest/relationship or affiliation in the form of Research grant, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis Pharmaceuticals Corporation. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.

Disclosure of Unlabeled Use

This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Provided by

COURSE VIEWING REQUIREMENTS